Samar M. Mahgoub, Abdelatty M. Radalla, Ahmed A. Allam, Haifa E. Alfassam, Rehab Mahmoud
{"title":"可持续反相高效液相色谱法同时定量溶菌酶和去qualinium：一种新的分析方法","authors":"Samar M. Mahgoub, Abdelatty M. Radalla, Ahmed A. Allam, Haifa E. Alfassam, Rehab Mahmoud","doi":"10.1007/s12247-025-09978-3","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>This study aims to develop and validate a novel reversed-phase high-performance liquid chromatography (RP-HPLC) method for the simultaneous quantification of lysozyme and dequalinium, two compounds with antimicrobial and anti-inflammatory properties. The research seeks to address the need for a reliable analytical tool for combination therapies targeting infections and inflammation, the study design is summarized in the Graphical Abstract.</p><h3>Methods</h3><p>The RP-HPLC method was optimized using a Zorbax 300 SB-C18 column at 60 °C, with a gradient mobile phase of trifluoroacetic acid and acetonitrile. The method was validated for linearity, detection limits, accuracy, precision, and robustness following ICH guidelines. Analytical performance was assessed in pharmaceutical formulations containing lysozyme and dequalinium.</p><h3>Results</h3><p>The method demonstrated excellent linearity (r2 > 0.999) in the concentration range of 3–50 µg/mL for both compounds. Detection limits were 2.60 µg/mL for lysozyme and 2.06 µg/mL for dequalinium. Recovery rates were close to 100%, indicating high accuracy and precision. The method also displayed robust performance with minimal variation in results.</p><h3>Conclusions</h3><p>The developed RP-HPLC method is efficient, reliable, and suitable for the simultaneous quantification of lysozyme and dequalinium in pharmaceutical formulations. It offers a promising analytical tool for quality control in combination therapies and demonstrates exceptional sustainability, as indicated by high greenness, blueness, and whiteness scores.</p><h3>Graphical Abstract</h3>\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 3","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sustainable RP-HPLC Method for Simultaneous Quantification of Lysozyme and Dequalinium: A Novel Analytical Approach\",\"authors\":\"Samar M. Mahgoub, Abdelatty M. Radalla, Ahmed A. Allam, Haifa E. Alfassam, Rehab Mahmoud\",\"doi\":\"10.1007/s12247-025-09978-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><p>This study aims to develop and validate a novel reversed-phase high-performance liquid chromatography (RP-HPLC) method for the simultaneous quantification of lysozyme and dequalinium, two compounds with antimicrobial and anti-inflammatory properties. The research seeks to address the need for a reliable analytical tool for combination therapies targeting infections and inflammation, the study design is summarized in the Graphical Abstract.</p><h3>Methods</h3><p>The RP-HPLC method was optimized using a Zorbax 300 SB-C18 column at 60 °C, with a gradient mobile phase of trifluoroacetic acid and acetonitrile. The method was validated for linearity, detection limits, accuracy, precision, and robustness following ICH guidelines. Analytical performance was assessed in pharmaceutical formulations containing lysozyme and dequalinium.</p><h3>Results</h3><p>The method demonstrated excellent linearity (r2 > 0.999) in the concentration range of 3–50 µg/mL for both compounds. Detection limits were 2.60 µg/mL for lysozyme and 2.06 µg/mL for dequalinium. Recovery rates were close to 100%, indicating high accuracy and precision. The method also displayed robust performance with minimal variation in results.</p><h3>Conclusions</h3><p>The developed RP-HPLC method is efficient, reliable, and suitable for the simultaneous quantification of lysozyme and dequalinium in pharmaceutical formulations. It offers a promising analytical tool for quality control in combination therapies and demonstrates exceptional sustainability, as indicated by high greenness, blueness, and whiteness scores.</p><h3>Graphical Abstract</h3>\\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>\",\"PeriodicalId\":656,\"journal\":{\"name\":\"Journal of Pharmaceutical Innovation\",\"volume\":\"20 3\",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-05-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmaceutical Innovation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s12247-025-09978-3\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Innovation","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12247-025-09978-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Sustainable RP-HPLC Method for Simultaneous Quantification of Lysozyme and Dequalinium: A Novel Analytical Approach
Purpose
This study aims to develop and validate a novel reversed-phase high-performance liquid chromatography (RP-HPLC) method for the simultaneous quantification of lysozyme and dequalinium, two compounds with antimicrobial and anti-inflammatory properties. The research seeks to address the need for a reliable analytical tool for combination therapies targeting infections and inflammation, the study design is summarized in the Graphical Abstract.
Methods
The RP-HPLC method was optimized using a Zorbax 300 SB-C18 column at 60 °C, with a gradient mobile phase of trifluoroacetic acid and acetonitrile. The method was validated for linearity, detection limits, accuracy, precision, and robustness following ICH guidelines. Analytical performance was assessed in pharmaceutical formulations containing lysozyme and dequalinium.
Results
The method demonstrated excellent linearity (r2 > 0.999) in the concentration range of 3–50 µg/mL for both compounds. Detection limits were 2.60 µg/mL for lysozyme and 2.06 µg/mL for dequalinium. Recovery rates were close to 100%, indicating high accuracy and precision. The method also displayed robust performance with minimal variation in results.
Conclusions
The developed RP-HPLC method is efficient, reliable, and suitable for the simultaneous quantification of lysozyme and dequalinium in pharmaceutical formulations. It offers a promising analytical tool for quality control in combination therapies and demonstrates exceptional sustainability, as indicated by high greenness, blueness, and whiteness scores.
期刊介绍：
The Journal of Pharmaceutical Innovation (JPI), is an international, multidisciplinary peer-reviewed scientific journal dedicated to publishing high quality papers emphasizing innovative research and applied technologies within the pharmaceutical and biotechnology industries. JPI''s goal is to be the premier communication vehicle for the critical body of knowledge that is needed for scientific evolution and technical innovation, from R&D to market. Topics will fall under the following categories:
Materials science,
Product design,
Process design, optimization, automation and control,
Facilities; Information management,
Regulatory policy and strategy,
Supply chain developments ,
Education and professional development,
Journal of Pharmaceutical Innovation publishes four issues a year.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
